Analytical Data
-
Gene name
IL-23 alpha
- Application
-
Alternative Names
P19; IL23P19; SGRF
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
> 90% as determined by SDS-PAGE.
-
Uniprot
Q91Z84
-
Expression Region
Ser37~Ala196
-
Molecular Weight
48kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-23 (IL-23) is a cytokine that plays a crucial role in the immune response, particularly in the differentiation and maintenance of pro-inflammatory T-helper 17 (Th17) cells. Elevated levels of IL-23 have been implicated in a variety of inflammatory diseases, including psoriasis, inflammatory bowel disease, and multiple sclerosis, positioning it as a significant target for therapeutic intervention. Research on IL-23 has gained momentum as understanding its biological functions can lead to novel treatments for these conditions. The IL-23 alpha subunit, a component of the IL-23 heterodimer, is of particular interest because it is essential for the stability and activity of the cytokine. Recombinant forms of IL-23 alpha protein have been developed for both research and therapeutic purposes, serving as crucial tools in elucidating the mechanisms of IL-23-mediated signaling pathways and in testing new therapeutic agents that can block or modulate IL-23 activity. The ongoing studies on IL-23 alpha not only aim to further comprehend its role in immune regulation but also seek to validate its efficacy and safety in clinical settings, enhancing the prospects of targeted therapies against inflammatory diseases. Overall, the exploration of IL-23 alpha recombinants continues to advance our understanding of immune dysregulation and contribute to the development of innovative treatment strategies.
